	US 11,723,967 B2
	Zika virus vaccine
Benjamin Petsch, Tübingen (DE); Edith Jasny, Stuttgart (DE); and Yves Girerd-Chambaz, Messimy (FR)
Assigned to CureVac SE, Tübingen (DE); and Sanofi Pasteur, Lyons (FR)
Appl. No. 15/999,469
Filed by CureVac SE, Tübingen (DE); and Sanofi Pasteur, Lyons (FR)
PCT Filed Feb. 17, 2017, PCT No. PCT/EP2017/053721 § 371(c)(1), (2) Date Aug. 17, 2018, PCT Pub. No. WO2017/140905, PCT Pub. Date Aug. 24, 2017.
Claims priority of application No. PCT/EP2016/053398 (WO), filed on Feb. 17, 2016.
Prior Publication US 2021/0205434 A1, Jul. 8, 2021
Int. Cl. A61K 39/12 (2006.01); A61K 47/64 (2017.01); A61P 31/14 (2006.01); A61K 39/385 (2006.01); C07K 14/005 (2006.01)

CPC A61K 39/12 (2013.01) [A61K 39/385 (2013.01); A61K 47/646 (2017.08); A61K 47/6455 (2017.08); A61P 31/14 (2018.01); C07K 14/005 (2013.01)]

15 Claims

1. An artificial nucleic acid comprising at least one coding region encoding at least one polypeptide comprising Zika virus envelope protein (E), wherein the artificial nucleic acid is a mRNA comprising, in 5′ to 3′ direction, the following elements:

a) a 5′-CAP structure,

b) the at least one coding region comprising a modified nucleic acid sequence encoding the at least one polypeptide comprising Zika virus envelope protein (E), wherein the at least one polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO: 552, wherein the at least one coding region comprises a nucleic acid sequence identical to the polypeptide coding region of SEQ ID NO: 5520 or a sequence at least 95% identical to the polypeptide coding region of SEQ ID NO: 5520,

c) a heterologous 3′-UTR element comprising a nucleic acid sequence, and

d) a poly(A) sequence comprising 10 to 200 adenosine nucleotides.